The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma

被引：0
|
作者：
Rachna T Shroff
Mark Yarchoan
Ashley O'Connor
Denise Gallagher
Marianna L Zahurak
Gary Rosner
Chimela Ohaji
Susan Sartorius-Mergenthaler
Vivek Subbiah
Ralph Zinner
Nilofer S Azad
机构：
[1] The University of Texas MD Anderson Cancer Center,
[2] Gastrointestinal Oncology,undefined
[3] Sidney Kimmel Comprehensive Cancer Center,undefined
[4] Johns Hopkins University,undefined
来源：
British Journal of Cancer | 2017年 / 116卷
关键词：
cholangiocarcinoma; trametinib; MEK; pazopanib; VEGF; RAS; angiogenesis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1402 / 1407
页数：5
相关论文
共 50 条
  • [41] A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
    Infante, Jeffrey R.
    Somer, Bradley G.
    Park, Joon Oh
    Li, Chung-Pin
    Scheulen, Max E.
    Kasubhai, Saifuddin M.
    Oh, Do-Youn
    Liu, Yuan
    Redhu, Suman
    Steplewski, Klaudia
    Le, Ngocdiep
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (12) : 2072 - 2081
  • [42] A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors
    Khalid Jazieh
    Julian Molina
    Jacob Allred
    Jun Yin
    Joel Reid
    Matthew Goetz
    Vun-Sin Lim
    Scott H. Kaufmann
    Alex Adjei
    Investigational New Drugs, 2019, 37 : 307 - 314
  • [43] Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models
    Dev, IK
    Dornsife, RE
    Hopper, TM
    Onori, JA
    Miller, CG
    Harrington, LE
    Dold, KM
    Mullin, RJ
    Johnson, JH
    Crosby, RM
    Truesdale, AT
    Epperly, AH
    Hinkle, KW
    Cheung, M
    Stafford, JA
    Luttrell, DK
    Kumar, R
    BRITISH JOURNAL OF CANCER, 2004, 91 (07) : 1391 - 1398
  • [44] Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models
    I K Dev
    R E Dornsife
    T M Hopper
    J A Onori
    C G Miller
    L E Harrington
    K M Dold
    R J Mullin
    J H Johnson
    R M Crosby
    A T Truesdale
    A H Epperly
    K W Hinkle
    M Cheung
    J A Stafford
    D K Luttrell
    R Kumar
    British Journal of Cancer, 2004, 91 : 1391 - 1398
  • [45] Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors
    Langenberg, Marlies H. G.
    Witteveen, Petronella O.
    Roodhart, Jeanine M.
    Verheul, Henk M. W.
    Mergui-Roelvink, Marja
    van der Sar, Jana
    Brendel, Erich
    Laferriere, Nicole
    Schellens, Jan H. M.
    Voest, Emile E.
    CLINICAL CANCER RESEARCH, 2010, 16 (07) : 2187 - 2197
  • [46] A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors
    Nakamichi, Shinji
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Yamada, Yasuhide
    Honda, Kazunori
    Tamura, Yosuke
    Wakui, Hiroshi
    Sasaki, Tatsuya
    Yusa, Wataru
    Fujino, Katsuki
    Tamura, Tomohide
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (06) : 1153 - 1161
  • [47] A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors
    Shinji Nakamichi
    Hiroshi Nokihara
    Noboru Yamamoto
    Yasuhide Yamada
    Kazunori Honda
    Yosuke Tamura
    Hiroshi Wakui
    Tatsuya Sasaki
    Wataru Yusa
    Katsuki Fujino
    Tomohide Tamura
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 1153 - 1161
  • [48] Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations
    Bardia, Aditya
    Gounder, Mrinal
    Rodon, Jordi
    Janku, Filip
    Lolkema, Martijn P.
    Stephenson, Joe J.
    Bedard, Philippe L.
    Schuler, Martin
    Sessa, Cristiana
    LoRusso, Patricia
    Thomas, Michael
    Maacke, Heiko
    Evans, Helen
    Sun, Yongjian
    Tan, Daniel S. W.
    ONCOLOGIST, 2020, 25 (01) : E160 - E169
  • [49] Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma
    Sonpavde, Guru
    Hutson, Thomas E.
    Sternberg, Cora N.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (02) : 253 - 261
  • [50] Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy
    Booth, Andrew E. C.
    Hopkins, Ashley M.
    Rowland, Andrew
    Kichenadasse, Ganessan
    Smith, Justine R.
    Sorich, Michael J.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
12345